Keyphrases
Prostate Cancer
100%
Pharmacological Inhibitors
100%
Non-canonical
100%
Chemoresistance
100%
Enhancer of Zeste Homolog 2 (EZH2)
100%
Embryonic Ectoderm Development
100%
Chemoresistant
80%
Prostate Cancer Cells
40%
Specific Inhibitor
20%
Mechanism of Action
20%
High Potency
20%
Phosphorylation
20%
Clinically Significant
20%
Clinical Outcomes
20%
Standard of Care
20%
Protein Degradation
20%
Cellular Approach
20%
Prostate Cancer Patients
20%
Molecular Approaches
20%
Signaling Cascades
20%
In Vivo Growth
20%
In Vivo Efficacy
20%
Docetaxel
20%
In Vitro Toxicity
20%
Signal Transducer and Activator of Transcription 3
20%
ATP-binding Cassette Transporter A1 (ABCA1)
20%
Computational Approach
20%
Cancer Resistance
20%
Prostate Radiotherapy
20%
Xenograft Model
20%
High Selectivity
20%
Survival Signaling
20%
Phenotypic Screening
20%
Survivin
20%
Screening Platform
20%
S-phase Kinase-associated Protein 2 (Skp2)
20%
Docetaxel Resistance
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Drug Resistance
100%
Transcription Factor EZH2
100%
Lead Compound
50%
Docetaxel
25%
Adenosine Triphosphate
12%
STAT3 Protein
12%
Survivin
12%
S Phase Kinase Associated Protein 2
12%